drugset
drugset / Trial / NCT03864458

Dose-finding Study of KHK7791 in Hyperphosphatemia Patients

NCT03864458 ↗

Phase 2 Completed 207 enrolled Kyowa Kirin, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the effect and safety of KHK7791 to treat Hyperphosphatemia in ptatients on HD.

Timeline

Start
2019-04-15
Primary completion
2019-12-10
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenapanor Small molecule — Oral

Indications

hyperphosphatemia